Bourbeau Jean, Sedeno Maria, Li Pei Zhi, Troosters Thierry, Hamilton Alan, De Sousa Dorothy, Maltais François, Erzen Damijan, Lavoie Kim L
Research Institute of the McGill University Health Centre, Montréal, Canada.
Dept of Rehabilitation Sciences, University of Leuven, Leuven, Belgium.
ERJ Open Res. 2021 Mar 29;7(1). doi: 10.1183/23120541.00533-2020. eCollection 2021 Jan.
In this analysis of the PHYSACTO® study, we assessed the efficacy of a self-management behaviour modification (SMBM) programme to improve physical activity (PA) levels, and the extent to which effects were mediated by readiness to change, motivation and confidence.
PHYSACTO® was a randomised, partially double-blind, parallel-group, 12-week trial to evaluate the effects of treatment on exercise capacity and PA. COPD patients received placebo, tiotropium 5 µg or tiotropium/olodaterol 5/5 µg, with or without exercise training, all with an SMBM intervention (the Living Well with COPD programme). Changes were assessed in readiness to change (stage of change visual analogue scale [VAS]), motivation (Treatment Self-Regulation Questionnaire [TSRQ]) and confidence (Perceived Competence Scale [PCS]) to engage in PA.
PA was increased in all patients with complete PA data at Week 12 (n=262; +6038 steps·week, p<0.001). Significant increases were observed in patients' readiness to change (VAS 0.7 [0.6-0.8]), autonomous regulation (TRSQ 0.2 [0.1-0.3]) and confidence (PCS 0.5 [0.3-0.6]) (all p<0.01). Of note, 23% of the total effect of SMBM on steps·week was found to be mediated by increases in readiness to change, 5% by TSRQ autonomous regulation and 12% by PCS.
Our study demonstrated that an SMBM programme delivered to COPD patients increased PA, mediated by an improvement of three key hypothesised mechanisms of change: readiness to change, autonomous motivation and confidence. For the first time, this study shows that an SMBM programme can be successful in altering the mechanisms of change targeted by the intervention.
在本次对PHYSACTO®研究的分析中,我们评估了自我管理行为改变(SMBM)计划对提高身体活动(PA)水平的疗效,以及改变意愿、动机和信心对该效果的介导程度。
PHYSACTO®是一项随机、部分双盲、平行组、为期12周的试验,旨在评估治疗对运动能力和PA的影响。慢性阻塞性肺疾病(COPD)患者接受安慰剂、5μg噻托溴铵或5/5μg噻托溴铵/奥达特罗治疗,同时接受或不接受运动训练,所有患者均接受SMBM干预(COPD健康生活计划)。评估患者参与PA的改变意愿(改变阶段视觉模拟量表[VAS])、动机(治疗自我调节问卷[TSRQ])和信心(自我效能感量表[PCS])。
在第12周时,所有具有完整PA数据的患者(n = 262)的PA均有所增加(每周增加6038步,p < 0.001)。患者的改变意愿(VAS为0.7[0.6 - 0.8])、自主调节(TSRQ为0.2[0.1 - 0.3])和信心(PCS为0.5[0.3 - 0.6])均有显著增加(所有p < 0.01)。值得注意的是,SMBM对每周步数的总效应中,23%由改变意愿的增加介导,5%由TSRQ自主调节介导,12%由PCS介导。
我们的研究表明,向COPD患者提供的SMBM计划可增加PA,这是由三个关键的假设改变机制的改善介导的:改变意愿、自主动机和信心。本研究首次表明,SMBM计划可以成功改变干预所针对的改变机制。